GleamWall
中文EN

SLS SELLAS Life Sciences Group, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1390478 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-40.3%
ROA-37.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio14.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0———$0———
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0———$0———
R&D expense$7.03M$6.27M$5.13M$4.73M$4.22M$3.87M$3.21M$4.44M
SG&A expense$4.28M$4.36M$4.12M$3.52M$2.87M$3.00M$2.86M$2.48M
Operating income-$11.31M-$10.63M-$9.25M-$8.26M-$7.08M-$6.87M-$6.06M-$6.92M
Net income-$10.09M-$9.61M-$8.41M-$7.66M-$6.79M-$6.60M-$5.81M-$6.74M
EPS (basic)-0.05-0.05-0.05—-0.06-0.07-0.07—
EPS (diluted)-0.05-0.05-0.05—-0.06-0.07-0.07—
Weighted avg. shares (diluted)202.44M189.18M172.48M—108.40M98.56M87.76M—
Balance sheet
Cash & equivalents$134.71M$138.34M$107.10M$71.79M$44.42M$25.40M$28.50M$13.99M
Current assets$138.57M$142.50M$111.17M$75.21M$49.05M$29.45M$31.97M$16.33M
Goodwill$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M
Total assets$141.09M$145.38M$114.18M$78.34M$51.55M$32.30M$34.96M$19.43M
Current liabilities$9.29M$7.57M$6.46M$7.02M$5.92M$6.00M$6.89M$9.51M
Total liabilities$9.29M$7.73M$6.76M$7.47M$5.92M$6.16M$7.20M$9.97M
Shareholders' equity$131.81M$137.66M$107.41M$70.87M$45.63M$26.15M$27.76M$9.46M
Shares outstanding203.53M201.92M181.33M153.10M125.08M100.37M90.90M73.98M
Cash flow statement
Operating cash flow-$5.94M-$7.59M-$8.85M-$4.92M-$7.07M-$7.33M-$9.07M-$7.15M
Investing cash flow———————$0
Financing cash flow$2.31M$38.83M$44.15M$32.39M$26.09M$4.23M$23.58M$8,000
Stock-based compensation$1.93M$1.01M$798,000$447,000$503,000$501,000$505,000$373,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.